Industry

Co-led by Horizons Ventures and OurCrowd, new funding enables SaNOtize to invest in its ongoing Phase 3 clinical trial for COVID-19 prevention and enhance clinical development of its other nitric oxide-based therapeutics SaNOtize’s Nitric Oxide Nasal Spray (NONS™) has been clinically shown to treat COVID-19 in high-risk adult patients and to prevent infections when used … [Read more…]

SEATTLE–(BUSINESS WIRE)–Critical Insight, a Managed Detection and Response (MDR) service provider specializing in protecting the networks of life-saving organizations and critical infrastructure, announced today the release of the firm’s H1 2022 Healthcare Data Breach Report, which analyzes ​​breach data reported to the U.S. Department of Health and Human Services by healthcare organizations. With the healthcare … [Read more…]

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that four posters and one oral presentation will be presented at the European Society of Cardiology (ESC) Congress 2022, taking place August 26-29, 2022, and the European Respiratory Society (ERS) International Congress 2022, taking place September … [Read more…]

SALT LAKE CITY–(BUSINESS WIRE)–iVeena Delivery Systems Inc. (“iVeena”), a clinical stage biopharmaceutical company with developmental products in keratoconus and pediatric myopia, has entered into a strategic licensing agreement with Glaukos Corporation (NYSE: GKOS) that grants Glaukos an exclusive global license to develop and commercialize IVMED-80, a pharmacologic treatment for keratoconus. Keratoconus, a rare corneal disorder, … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Global Breast Cancer Clinical Trial Pipeline Highlights – 2022” report has been added to ResearchAndMarkets.com’s offering. The report provides the most up-to-date information on key pipeline products in the global Breast Cancer market. It covers emerging therapies for Breast Cancer in active clinical development stages including early and late stage clinical trials. The … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Peptide Therapeutics Market Intelligence Report – Global Forecast to 2027” report has been added to ResearchAndMarkets.com’s offering. The Global Peptide Therapeutics Market is projected to reach USD 50.72 billion by 2027 from USD 27.13 billion in 2021, at a CAGR 10.99% during the forecast period. In this report, the years 2019 and 2020 … [Read more…]

Company will analyze longitudinal biological samples and clinical data to identify molecular pathways associated with healthy longevity, leading to development of drug targets for diseases of aging RICHMOND, Calif.–(BUSINESS WIRE)–#aging–BioAge Labs, Inc. (“BioAge”, “the Company”), a biotechnology company developing therapeutics that target the molecular causes of aging to extend healthy human lifespan, today announced that … [Read more…]

From August 26th to 28th, 30 Korean companies exhibit and sell their excellent products in Jakarta, Indonesia CHEONGJU, South Korea & JAKARTA, Indonesia–(BUSINESS WIRE)–#2022ChungbukBestProductPromotion–Chungcheongbuk-do has started to secure export channels for promising exporters in North Chungcheong Province to the Indonesian market. 2022 CHUNGBUK BEST PRODUCT PROMOTION will be held by Chungcheongbuk-do and Chungbuk Business Agency … [Read more…]

Series B financing will accelerate growth and advance lead clinical program 212Pb-ADVC001 a best-in-class treatment for metastatic prostate cancer, expand manufacturing platform footprint and progress internal and partnership programs. SYDNEY–(BUSINESS WIRE)–#AdvanCell–AdvanCell, an Australian radiopharmaceutical company with a platform technology for a revolutionary cancer treatment called Targeted Alpha Therapy, announced today the closing of an A$18 … [Read more…]

BEIJING–(BUSINESS WIRE)–InnoCare Pharma (HKEX: 09969) and Keymed Biosciences (HKEX: 02162) jointly announced today that the Investigational New Drug (IND) of CM369, an anti-CC chemokine receptor 8 (CCR8) monoclonal antibody, developed by a joint venture between the two companies called Tiannuojiancheng Pharma, has been approved by the China’s National Medical Products Administration (NMPA). CM369 is a … [Read more…]